Risk factors and clinical outcomes of cytomegalovirus disease occurring more than one year post solid organ transplantation

Transplant Infectious Disease

Volumn 14, Issue 2, 2012, Pages 149-155

  Blyth, D ^a   Lee, I ^b,c   Sims, K D ^b,d   Gasink, L B ^b,e   Barton, T D ^b   Van Deerlin, V M ^b   Pfeiffenberger, P ^b   Blumberg, E A ^b  

^a San Antonio Uniformed Services Health Education Consortium   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Cytomegalovirus; Late infection; Organ transplant; Risk factors; Survival

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN; LEUKOCYTE ANTIBODY; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; SERUM ALBUMIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COMORBIDITY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SOLID ORGAN TRANSPLANTATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RISK FACTORS; TIME FACTORS; VIREMIA;

EID: 84859848840     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00705.x     Document Type: Article

References (16)

1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357 (25): 2601-2614.
2. Slifkin M, Tempesti P, Poutsiaka DD, Snydman DR. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2001; 33 (7): E62-E68.
3. Meylan PR, Manuel O. Late-onset cytomegalovirus disease in patients with solid organ transplant. Curr Opin Infect Dis 2007; 20 (4): 412-418.
4. Boehler A, Schaffner A, Salomon F, Keusch G. Cytomegalovirus disease of late onset following renal transplantation: a potentially fatal entity. Scand J Infect Dis 1994; 26 (4): 369-373.
5. Shibolet O, Ilan Y, Kalish Y, et al. Late cytomegalovirus disease following liver transplantation. Transpl Int 2003; 16 (12): 861-865.
6. Singh N, Zeevi A, Gayowski T, Marino IR. Late onset cytomegalovirus disease in liver transplant recipients: de novo reactivation in recurrent hepatitis C virus hepatitis. Transpl Int 1998; 11 (4): 308-311.
7. San Juan R, Aguado JM, Lumbreras C, et al.; RESITRA Network, Spain. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant 2007; 7 (4): 964-971.
8. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10 (5): 1228-1237.
9. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152 (12): 761-769.
10. Caliendo AM, Ingersoll J, Fox-Canale AM, et al. Evaluation of real-time PCR laboratory-developed tests using analyte-specific reagents for cytomegalovirus quantification. J Clin Microbiol 2007; 45 (6): 1723-1727.
11. Humar A, Michaels M, AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6 (2): 262-274.
12. Humar A, Snydman D, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S78-S86.
13. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66 (1): 329-337.
14. McDonald K, Rector TS, Braulin EA, Kubo SH, Olivari MT. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol 1989; 64 (5): 359-362.
15. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomized controlled trials. Lancet 2005; 365 (9477): 2105-2115.
16. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8 (5): 975-983.